•
•
•
•
•
•
•
.webp6ce22ba3-9fe3-4c8e-b989-2bbd27817374.webp)
Vaxiflu 2026–27 is an inactivated influenza vaccine marketed by Zydus Lifesciences in India. Product information lists it as a vaccine for protection against influenza and says it should be administered by a doctor or trained healthcare professional rather than self-injected.
The vaccine is described by INVC as a trivalent influenza vaccine, covering three influenza virus groups: A(H1N1), A(H3N2) and B/Victoria.
Influenza A(H1N1) is commonly associated with the term “swine flu,” although H1N1 is now part of the broader seasonal influenza viruses circulating in humans.
Influenza viruses continually change, which is why seasonal flu vaccines are reviewed and updated regularly.
For the 2026–27 U.S. flu season, the CDC says all three vaccine components were updated compared with the previous season. The recommended trivalent composition includes an H1N1 component, an H3N2 component and a B/Victoria component.
This annual updating is one reason people are generally advised to receive the appropriate seasonal influenza vaccine each year.
Current CDC guidance recommends annual influenza vaccination for people aged 6 months and older, unless they have a contraindication.
For Vaxiflu specifically, product information indicates that it can be used in children from 6 months of age, adults and seniors, with dosing depending on age and previous influenza vaccination history.
Some young children receiving influenza vaccination for the first time may require two doses at least four weeks apart, while older children and adults generally receive one dose for the season. The exact schedule should be confirmed with a healthcare professional.
Vaxiflu is administered as an intramuscular injection by a trained healthcare professional. Product information identifies the upper arm or thigh as possible injection sites depending on age and circumstances.
It is not intended for self-administration.
Like other flu vaccines, vaccination does not treat an existing influenza infection. Protection also takes time to develop; CDC notes that antibodies generally develop about two weeks after vaccination.
Flu vaccines are generally well tolerated. Reported reactions can include:
These reactions are usually short-lived.
People who have experienced a severe allergic reaction to a previous influenza vaccine or a component of the vaccine should discuss vaccination with their healthcare provider before receiving another dose.
Vaxiflu 2026–27 is an updated influenza vaccine available in India from Zydus. Its listed trivalent formulation targets H1N1, H3N2 and B/Victoria, the three virus groups represented in current trivalent influenza vaccines.
Because vaccine suitability and dosing can vary by age, previous vaccination history, allergies and medical conditions, people should consult a qualified healthcare professional before vaccination.
